References
- Giovannuci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a
consensus report. Diabetes Care. 2010;33(7):1674–85.
- Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast
cancer outcomes: a systematic review and meta-analysis. J Clin Oncol.
2011; 29: 40–6.
- Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as
first-line chemotherapy for advanced nonsmall cell lung cancer in
patients with type 2 diabetes. Cancer 117(22): 5103–5111.
- S.C. Larsson, A. Wolk, Diabetes mellitus and incidence of kidney
cancer: a meta-analysis of cohort studies. Diabetologia 2011;54(5),
1013–1018.
- Feng X, Wang G, Li N, et al. The association between fasting blood
glucose and the risk of primary liver cancer in Chinese males: a
population‐based prospective study. Br J Cancer 2017; 117: 1405.
- Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and
prostate cancer risk: a nationwide case‐control study within PCBaSe
Sweden. Cancer Epidemiol Biomarkers Prev 2013; 22: 1102–09.
- Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of
prostate cancer: a meta‐analysis. Diabetologia 2004; 47: 1071–78.
- Kasper J, Giovannucci E. A meta‐analysis of diabetes mellitus and the
risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:
2056
- Lawrence YR, Morag O, Benderly M, et al. Association between metabolic
syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer
Prostatic Dis. 2013; 16: 181–186.
- Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE.
Diabetes and risk of prostate cancer in a prospective cohort of US
men. Am J Epidemiol. 2005; 161: 147–152.
- Tseng CH. Diabetes and risk of prostate cancer: a study using the
National Health Insurance. Diabetes Care. 2011; 34: 616–621.
- Li Q, Kuriyama S, Kakizaki M, et al. History of diabetes mellitus and
the risk of prostate cancer: the Ohsaki CohortStudy. Cancer Causes
Control. 2010; 21: 1025-32
- Peehl DM, Stamey TA. Serum-free growth of adult human prostatic
epithelial cells. In Vitro Cell Dev Biol. 1986; 22(2):82-90.
- Wright JL, Plymate SR, Porter MP, et al. Hyperglycemia and prostate
cancer recurrence in men treated for localized prostate cancer.
Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):204-8.
- Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products:
a review. Diabetologia. 2001; 44(2):129-46.
- Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their
relevance to diabetic complications? Diabetes Obes Metab. 2007;
9(3):233–245
- Monnier VM, Sell DR, Nagaraj RH, et al. Maillard reaction-mediated
molecular damage to extracellular matrix and other tissue proteins in
diabetes, aging, and uremia. Diabetes. 1992; 41 Suppl 2():36-41.
- Goh SY, Cooper ME. Clinical review: The role of advanced glycation end
products in progression and complications of diabetes. J Clin
Endocrinol Metab. 2008; 93(4):1143-52.
- Li T, Qin W, Liu Y, et al. Effect of RAGE gene polymorphisms
and circulating sRAGE levels on susceptibility to gastric cancer: a
case-control study. Cancer Cell Int. 2017
- Nankali M, Karimi J, Goodarzi M, et al. TIncreased Expression of the
Receptor for Advanced Glycation End-Products (RAGE) Is Associated
with Advanced Breast Cancer Stage. Oncol Res Treat. 2016; 39:622-628
- Nguyen AH, Detty SQ, Agrawal DK. Clinical Implications of
High-mobility Group Box-1 (HMGB1) and the Receptor
for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A
Systematic Review. Anticancer Res. 2017; 37(1):1-7
- Kang R, Tang D, Schapiro NE, et al. The HMGB1/RAGE inflammatory
pathway promotes pancreatic tumor growth by regulating mitochondrial
bioenergetics. Oncogene. 2014; 33:567–577.
- Yang S, Pinney SM, Mallick P, et al. Impact of Oxidative Stress
Biomarkers and Carboxymethyllysine (an AdvancedGlycation End Product)
on Prostate Cancer: A Prospective Study. Clin Genitourin Cancer. 2015;
13(5):347-51
- Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society
of Urological Pathology (ISUP) Consensus Conference on Gleason Grading
of Prostatic Carcinoma: definition of grading patterns and proposal
for a new grading system. Am J Surg Pathol (2016) 40(2):244–249
- Moul JW: Prostate specific antigen only progression of prostate
cancer. J Urol 2000; 163: 1632–1642.
- Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific
survival following salvage radiotherapy vs observation in men with
biochemical recurrence after radical prostatectomy. JAMA 2008;
299:27609.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). EJC
2009; 45:228–47.
- Xu XC, Abuduhadeer X, Zhang WB, et al (2013). Knockdown of RAGE
inhibits growth and invasion of gastric cancer Cells. Eur J
Histochem , 29, 240-6.
- Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H.
Receptor for advanced glycation end products (RAGE) and its ligand,
amphoterin are overexpressed and associated with prostate cancer
development. The Prostate. 2005; 64:92–100.
- Cai H, Xu Z, Xu T, et al. Diabetes mellitus is associated with
elevated risk of mortality amongst patients with prostate cancer: a
meta-analysis of 11 cohort studies. Diabetes Metab Res Rev. 2015;
31(4):336-43
- Chen M, Luo Y, Yang S, et al. Association of diabetes
mellitus with prostate cancer grade and prostate-specific antigen in
Chinese biopsy population. Diabetes research and clinical
practice 141 (2018): 80-87.
- Tsilidis KK, Allen NE, Appleby PN, et al. Diabetes mellitus and risk
of prostate cancer in the European Prospective Investigation
into Cancer and Nutrition. Int J Cancer 2015;136(2):372-81
- Xu H, Jiang HW, Ding GX, et al. Diabetes mellitus and prostate
cancer risk of different grade or stage: a systematic review and
meta-analysis. Diabetes Clin Res Pract 2013; 99(3):241-9
- Moreira DM, Anderson T, Gerber L, et al. The association of diabetes
mellitus and high-grade prostate cancer in a multiethnic biopsy
series. Cancer Causes Control. 2011; 22:977–983
- Fukushima H, Masuda H, Kawakami S, et al. Effect of diabetes mellitus
on high-grade prostate cancer detection among Japanese obese patients
with prostate-specific antigen less than 10 ng/mL. Urology. 2012;
79:1329–1334.
- Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J
Impot Res. 2003; 15(Suppl 4): S14–S20.
- Peskoe SB, Joshu CE, Rohrmann S, et al. Circulating total testosterone
and PSA concentrations in a nationally representative sample of men
without a diagnosis of prostate cancer. Prostate. 2015; 75:1167–1176.
- Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in
men with non-insulin-dependent diabetes mellitus. Ann Intern
Med. 1992; 117:807–811.
- Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes,
and obesity-related health risk factors, 2001. Jama. 2003; 289:76–79.
- Drinda S, Franke S, Ruster M, et al. Identification of the receptor
for advanced glycation end products in synovial tissue of patients
with rheumatoid arthritis. Rheumatol Int. 2005; 25:411–413.
- Hu P, Lai D, Lu P, Gao J, He H. ERK and Akt signaling pathways are
involved in advanced glycation end product-induced autophagy in rat
vascular smooth muscle cells. Int J Mol Med. 2012; 29:613–618.
- Yuan X, Zhang Z, Gong K, Zhao P, Qin J, Liu N. Inhibition of reactive
oxygen species/extracellular signal-regulated kinases pathway by
pioglitazone attenuates advanced glycation end products-induced
proliferation of vascular smooth muscle cells in rats. Biol Pharm
Bull. 2011; 34:618–623.
- Zhang J, Shao S, Han D, et al. High mobility group box 1 promotes the
epithelial-to-mesenchymal transition in prostate cancer PC3 cells via
the RAGE/NF-κB signaling pathway. Int J Oncol. 2018; 53(2):659-671
- Zhao C, Bao J, Lu Y, et al. Co-expression of RAGE and HMGB1 is
associated with cancer progression and poor patient outcome of
prostate cancer. Am J Cancer Res. American journal of cancer
research 4.4 (2014): 369.
- Baillargeon J, Pollock BH, Kristal AR, et al. The association of body
mass index and prostate-specific antigen in a population-based
study. Cancer. 2005; 103:1092–1095.
- McGinley KF, McMahon GC, Brown GA. Impact of the US Preventive
Services Task Force Grade D recommendation: assessment of evaluations
for elevated prostate-specific antigen and prostate biopsies in a
large urology group practice following statement revision. Rev
Urol . 2015; 17(3):171-177.
- Staquicini FI, Cardó-Vila M, Kolonin MG, et al. Vascular
ligand-receptor mapping by direct combinatorial selection in cancer
patients. Proc Natl Acad Sci U S A. 2011; 108(46):18637–42.
- Tateno T, Ueno S, Hiwatashi K, et al. Expression of receptor for
advanced glycation end products (RAGE) is related to prognosis in
patients with esophageal squamous cell carcinoma. Ann Surg Oncol.
2009; 16(2):440-6
- Fahmueller YN, Nagel D, Hoffmann RT, et al. Immunogenic cell death
biomarkers HMGB1, RAGE, and DNAse indicate response to
radioembolization therapy and prognosis in colorectal cancer patients.
Int J Cancer 2013; 132(10):2349-58
TABLE 1 Demographic, biochemical, histopathological parameters
and RAGE score of all three groups and subgroups (BPH-LPCa-MetPCa)